Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-incisional bupivacaine infusion for postoperative pain after intertrochanteric fracture surgery
IRCT20100127003213N8Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of bupivacaine and morphine in femoral fracture and intertrochanteric fracture (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Pain intensity during the first postoperative day and Total morphine administered during the first postoperative day. Started Mar 2019; status: completed.
02
Drugs
bupivacainemorphine
03
Conditions
femoral fractureintertrochanteric fracture
Beyond the preview
Go deeper on IRCT20100127003213N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100127003213N8.